BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 29483095)

  • 21. Tex10 is upregulated and promotes cancer stem cell properties and chemoresistance in hepatocellular carcinoma.
    Xiang X; Deng L; Xiong R; Xiao D; Chen Z; Yang F; Liu K; Feng G
    Cell Cycle; 2018; 17(11):1310-1318. PubMed ID: 30045663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma.
    Ou DL; Shyue SK; Lin LI; Feng ZR; Liou JY; Fan HH; Lee BS; Hsu C; Cheng AL
    Oncotarget; 2015 Sep; 6(29):27953-65. PubMed ID: 26172295
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AKR1B10 expression characteristics in hepatocellular carcinoma and its correlation with clinicopathological features and immune microenvironment.
    Ma LN; Ma Y; Luo X; Ma ZM; Ma LN; Ding XC
    Sci Rep; 2024 May; 14(1):12149. PubMed ID: 38802416
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SIRT7 regulates hepatocellular carcinoma response to therapy by altering the p53-dependent cell death pathway.
    Zhao J; Wozniak A; Adams A; Cox J; Vittal A; Voss J; Bridges B; Weinman SA; Li Z
    J Exp Clin Cancer Res; 2019 Jun; 38(1):252. PubMed ID: 31196136
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toll like receptor 4 facilitates invasion and migration as a cancer stem cell marker in hepatocellular carcinoma.
    Liu WT; Jing YY; Yu GF; Han ZP; Yu DD; Fan QM; Ye F; Li R; Gao L; Zhao QD; Wu MC; Wei LX
    Cancer Lett; 2015 Mar; 358(2):136-143. PubMed ID: 25511737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. lncARSR promotes liver cancer stem cells expansion via STAT3 pathway.
    Yang C; Cai WC; Dong ZT; Guo JW; Zhao YJ; Sui CJ; Yang JM
    Gene; 2019 Mar; 687():73-81. PubMed ID: 30391438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High expression of AKR1B10 predicts low risk of early tumor recurrence in patients with hepatitis B virus-related hepatocellular carcinoma.
    Wang YY; Qi LN; Zhong JH; Qin HG; Ye JZ; Lu SD; Ma L; Xiang BD; Li LQ; You XM
    Sci Rep; 2017 Feb; 7():42199. PubMed ID: 28181486
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tonicity-responsive enhancer-binding protein promotes stemness of liver cancer and cisplatin resistance.
    Lee JH; Suh JH; Kang HJ; Choi SY; Jung SW; Lee-Kwon W; Park SA; Kim H; Ye BJ; Yoo EJ; Jeong GW; Park NH; Kwon HM
    EBioMedicine; 2020 Aug; 58():102926. PubMed ID: 32739873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Smad inhibitor induces CSC differentiation for effective chemosensitization in cyclin D1- and TGF-β/Smad-regulated liver cancer stem cell-like cells.
    Xia W; Lo CM; Poon RYC; Cheung TT; Chan ACY; Chen L; Yang S; Tsao GSW; Wang XQ
    Oncotarget; 2017 Jun; 8(24):38811-38824. PubMed ID: 28415588
    [TBL] [Abstract][Full Text] [Related]  

  • 30. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
    Dai W; Xu L; Yu X; Zhang G; Guo H; Liu H; Song G; Weng S; Dong L; Zhu J; Liu T; Guo C; Shen X
    J Hepatol; 2020 May; 72(5):909-923. PubMed ID: 31899205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway.
    Li B; Cao Y; Meng G; Qian L; Xu T; Yan C; Luo O; Wang S; Wei J; Ding Y; Yu D
    EBioMedicine; 2019 Jan; 39():239-254. PubMed ID: 30555042
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice.
    Lo J; Lau EY; Ching RH; Cheng BY; Ma MK; Ng IO; Lee TK
    Hepatology; 2015 Aug; 62(2):534-45. PubMed ID: 25902734
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
    Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
    Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The ATP-binding cassette transporter ABCF1 is a hepatic oncofetal protein that promotes chemoresistance, EMT and cancer stemness in hepatocellular carcinoma.
    Fung SW; Cheung PF; Yip CW; Ng LW; Cheung TT; Chong CC; Lee C; Lai PB; Chan AW; Tsao GS; Wong CH; Chan SL; Lo KW; Cheung ST
    Cancer Lett; 2019 Aug; 457():98-109. PubMed ID: 31100412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC.
    Yin Y; Sun M; Zhan X; Wu C; Geng P; Sun X; Wu Y; Zhang S; Qin J; Zhuang Z; Liu Y
    J Exp Clin Cancer Res; 2019 Feb; 38(1):83. PubMed ID: 30770740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Krüppel-like factor 8 promotes cancer stem cell-like traits in hepatocellular carcinoma through Wnt/β-catenin signaling.
    Shen YN; He HG; Shi Y; Cao J; Yuan JY; Wang ZC; Shi CF; Zhu N; Wei YP; Liu F; Huang JL; Yang GS; Lu JH
    Mol Carcinog; 2017 Feb; 56(2):751-760. PubMed ID: 27478926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
    Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
    Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BORIS up-regulates OCT4 via histone methylation to promote cancer stem cell-like properties in human liver cancer cells.
    Liu Q; Chen K; Liu Z; Huang Y; Zhao R; Wei L; Yu X; He J; Liu J; Qi J; Qin Y; Li B
    Cancer Lett; 2017 Sep; 403():165-174. PubMed ID: 28645561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overexpression of ZFX confers self-renewal and chemoresistance properties in hepatocellular carcinoma.
    Lai KP; Chen J; He M; Ching AK; Lau C; Lai PB; To KF; Wong N
    Int J Cancer; 2014 Oct; 135(8):1790-9. PubMed ID: 24585547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma.
    Zheng M; Xu H; Liao XH; Chen CP; Zhang AL; Lu W; Wang L; Yang D; Wang J; Liu H; Zhou XZ; Lu KP
    Oncotarget; 2017 May; 8(18):29771-29784. PubMed ID: 28404959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.